Week in Review: China's Sanpower Pays $820 for Provenge, a Prostate Immunotherapy

Sanpower Group, a China conglomerate, paid $820 million for global rights to Provenge, an immunotherapy for prostate cancer, from Valeant Pharma; China radiology company Concord Medical formed a $150 million healthcare investment fund with Zhongrong International Trust; Shanghai Fosun Pharma announced a JV with Santa Monica's Kite Pharma to develop Kite's CAR-T immuno-oncology drug in China; Beijing's Cui Yutao Health Management Center raised $20 million in a C round for its pediatric care mobile app; Sequoia Capital China invested in Hong Kong Asia Medical Center, a China cardiology cancer hospital chain; AbbVie, Genomics Medicine Ireland, and WuXi NextCODE formed a genomic alliance to sequence 45,000 Irish genomes; Beijing's Bioyong Technology will bring Biodesix's VeriStrat® proteomic IVD to China; Suzhou Alphamab's anti-PD-L1 antibody was approved to begin China clinical trials; Chi-Med began treating cancer patients in a China Phase I trial of a novel Syk inhibitor; and Merck KGaA will offer an expanded set of biologic CRO/CMO services in Shanghai and Boston. More details.... Stock Symbols: (NYSE/TSX: VRX) (NYSE: CCM) (SHA:600196; HK:02196) (NSDQ: KITE) (NYSE: ABBV) NSDQ/AIM: HCM) (Xetra: MRK) Share this with colleagues: // //